Khandani, Amir H <br/><br/>
Primary renal cell carcinoma:  relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.  [electronic resource] 

 -  Nuclear medicine communications  Sep 2012 
 - 967-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5628 
<br/><br/><label>Standard No.: </label>10.1097/MNM.0b013e3283561837  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Benzenesulfonates--adverse effects<br/>Biological Transport<br/>Carcinoma, Renal Cell--diagnostic imaging<br/>Feasibility Studies<br/>Female<br/>Fluorodeoxyglucose F18--metabolism<br/>Humans<br/>Kidney Neoplasms--diagnostic imaging<br/>Male<br/>Middle Aged<br/>Multimodal Imaging<br/>Neoadjuvant Therapy--adverse effects<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Positron-Emission Tomography<br/>Pyridines--adverse effects<br/>Safety<br/>Sorafenib<br/>Survival Analysis<br/>Tomography, X-Ray Computed<br/>Treatment Outcome<br/>Young Adult